-The Times of India The cost of air-conditioners and refrigerators could go up considerably starting next summer if the US and other rich countries force a decision at the UN climate talks in November at Doha, to order a global ban on existing refrigerant gases and replace them with costly though relatively more climate-friendly alternatives. One of the alternatives being proposed is produced jointly by DuPont and Honeywell, two US-based multinationals, and...

-The Times of India Get ready to shell out more for your train journey and several other services provided by the government — from parcels to Patents. Pawan Kumar Bansal, the new railway minister, on Monday hinted at an increase in passenger fares with a caveat that it was not meant to earn a profit for the state-run transporter. "Fares will not be increased for the sake of increasing fare. If fare...

-IPS News Environmental activists are cautiously optimistic that a call by a court-appointed technical committee for a ten-year moratorium on open field trials of genetically modified (GM) crops will shelve plans to introduce bio-engineered foods in this largely agricultural country. “We are now waiting to see whether the Supreme Court will accept the recommendations of its own committee at the next hearing on Oct. 29,” said Devinder Sharma, chairman of the Forum...

-Outlook Hyderabad: India could win 105 claims on international Patents due to its Traditional Knowledge Digital Library (TKDL), Prime Minister Manmohan Singh said here today, opening the high-level segment meeting at the Conference of Parties to Convention on Biological Diversity. "We decided to build this knowledge database because of the patent on the use of neem extract in Europe and another patent on the use of turmeric as a healing agent. Since...

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...